MedTrace Logo

Instanyl® Non-Interventional Study

NCT01045603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 309

Last updated 2012-10-29

No results posted yet for this study

Summary

The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength. Data will be collected at three different time points over a 3 month period.

Conditions

  • Breakthrough Cancer Pain

Sponsors & Collaborators

Principal Investigators

  • Nycomed Clinical Trial Operations · Headquarters

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Denmark
  • France
  • Greece
  • Ireland
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01045603 on ClinicalTrials.gov